High-dose hyperfractionated SIB RT vs standard-dose RT (limited-stage SCLC) NCT03214003
ForLS-SCLC, age 18-70, ECOG 0-1, PET-CT staged, ≤2 prior chemo courses
TL;DRmOS 60.7 vs 39.5mo, HR 0.55 (0.37-0.72), p=0.003 for 54Gy SIB vs 45Gy BID, no added toxicity.
The dose went to GTV only: PTV stayed 45Gy in both arms, so this is an SIB boost, not a uniform 54Gy plan, and that is why grade 3-4 oesophagitis stayed at 13%. Local PFS HR 0.51 against a null MFS (HR 0.81) locates the benefit in the chest. Deliverable on VMAT with PET-defined involved fields.
In a fit LS-SCLC patient under 70 with PET-defined disease starting concurrent chemoRT, this supports an SIB boost to 54Gy/30 BID over uniform 45Gy; it does not speak to patients over 70, ECOG 2, or once-daily schedules.
The escalation is an SIB to GTV only, with PTV held at 45Gy in both arms, which is why grade 3-4 oesophagitis stayed at 13% vs 12%. Local PFS HR 0.51 against a null MFS (HR 0.81) confirms a chest-confined benefit. PET-defined involved fields, no elective nodal irradiation.
The chemotherapy backbone was fixed and identical (4 cycles platinum-etoposide, 99% completion in both arms), so the OS gain is attributable to the RT dose, not the regimen. Grade 3-4 neutropenia was unchanged at 44% vs 41%, so referring a fit under-70 patient for the boost schedule carries no extra haematologic cost.
10 details 1 trial watching
Open-label randomised phase 3, 16 public hospitals in China, 1:1, enrolled June 30 2017 to April 6 2021. Stratified by ECOG, stage, prior chemotherapy course, and platinum choice. Median follow-up 46 months (IQR 33-56); terminated early by the DSMB in April 2021 on interim benefit.
Aged 18-70, ECOG 0-1, VALSG limited-stage confirmed on whole-body FDG PET-CT and brain MRI, previously untreated or after one to two courses of platinum-etoposide. Median age 64, 46% female, 86% stage III, 79% current or former smokers. Age over 70 and ECOG 2 were excluded.
Four cycles of cisplatin 75 mg/m² (or carboplatin AUC 5) with etoposide 100 mg/m² days 1-3 every 3 weeks; 99% completed all four cycles in both arms. PCI 25 Gy in 10 fractions for responsive disease, given to 82% vs 81%.
VMAT, 6-MV, 30 twice-daily fractions over 3 weeks, minimum 6 h apart, starting 0-42 days after cycle 1. Experimental arm delivered a simultaneous integrated boost of 54 Gy to GTV/IGTV with the PTV at 45 Gy; the control arm had 45 Gy to both GTV and PTV. Target volumes were PET-positive lesions only, with elective nodal irradiation omitted and a 5 mm CTV margin.
Primary: overall survival in the ITT population, from the start of chemotherapy. Secondary: PFS, local PFS, metastatic-free survival, disease control rate, acute and late toxicity, and HRQOL (reported elsewhere).
No toxicity penalty for the boost: grade 3-4 oesophagitis 13% vs 12% (p=0.84) and pneumonitis 5% vs 6% (p=0.663). Grade 3-4 neutropenia 44% vs 41%. Late grade 3 pneumonitis in 2 vs 3 pts, no late grade 3 oesophagitis or pulmonary fibrosis in either arm. One treatment-related death (myocardial infarction, 54 Gy arm).
CONVERT (66 Gy in 33 once-daily fractions) and CALGB 30610/RTOG 0538 (70 Gy once daily) both failed to beat 45 Gy twice daily, with median OS 25 vs 30 mo and 28.5 vs 30.1 mo respectively. Neither escalated arm was hyperfractionated or accelerated. The Nordic phase 2 (60 Gy in 40 twice-daily fractions) did show a gain, 2-year OS 74.2% vs 48.1%, and this trial is the phase 3 counterpart of that signal.
Stopping at the interim analysis with 224 of a planned 326 pts inflates the observed effect, and the appendix-level subgroup analysis has not been done. There was no centralised QA of contouring or planning across the 16 centres, and prognostic variables that plausibly drive a dose effect (tumour volume, PTV size) were not balanced by design.
The 21.2-month OS gain is larger than the trial powered for (assumed HR 0.65, 37 vs 24 mo), and the control arm's 39.5 mo sits well above the 20.8-30 mo reported elsewhere for 45 Gy. That points to cohort selection (PET staging, VALSG limited stage, age and ECOG caps) rather than an underperforming control, which is reassuring for internal validity but limits transfer. Local PFS separating (HR 0.51) while MFS does not (HR 0.81) is the mechanistically coherent read for a dose escalation confined to the chest.
CONSORT flow
Randomised phase 3, prespecified OS primary hit at interim. Diverges from CONVERT/CALGB 30610 dose-escalation failures. Early stopping and single-country cohort temper it.
- Tolerability of 54Gy BID SIB in pts over 70
- Replication outside China with centralised RT quality assurance
- Optimal boost dose between 54Gy and 60Gy twice daily recruiting Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial Phase 3n=300 · primary completion 2028-09 · randomises 45 vs 60 vs SIB 45-54Gy BID
📚 Sources · 📄 1 paper
The longer read
The question this trial answers is narrower and more useful than "does dose escalation work in LS-SCLC." That broader question has been asked twice with once-daily schedules and answered no: CONVERT at 66 Gy in 33 fractions and CALGB 30610/RTOG 0538 at 70 Gy in 35 fractions both failed to improve on 45 Gy twice daily, and in CALGB the escalated arm's median survival ran slightly behind the control. What was untested at phase 3 was escalation that keeps the twice-daily, accelerated schedule intact. Holding the overall treatment time at 3 weeks in both arms is the design decision that makes this trial interpretable: the arms differ in dose to gross disease and in nothing else, so a positive result is attributable to dose rather than to the confound of a longer or shorter course that has muddied earlier comparisons.
The second design choice worth attention is the simultaneous integrated boost itself. The PTV prescription was 45 Gy in both arms; only the GTV or IGTV received 54 Gy in the experimental arm. This is not a uniform 54 Gy plan, and it explains why the toxicity comparison is as flat as it is, with grade 3-4 oesophagitis at 13% versus 12% and pneumonitis at 5% versus 6%. A reader tempted to translate this into a uniformly escalated plan would be leaving the trial's evidence behind and should expect the oesophagus to notice. The same caveat applies to target definition: every patient was staged with FDG PET-CT, elective nodal irradiation was omitted, and the boost volume was PET-positive disease. Escalating dose to a generously drawn elective volume is a different intervention with a different toxicity ceiling.
How much should the magnitude move confidence? Less than the headline implies. The trial was designed around an assumed hazard ratio of 0.65 with medians of 37 versus 24 months, and it stopped at a preplanned interim after 88 deaths with 224 of 326 planned patients accrued. Trials halted early for benefit systematically overstate effect size, and a 21.2-month median difference is a large overshoot of the design assumption. The direction of the result is well supported by the interim boundary being crossed on a properly specified spending function; the size of it is the part to discount. The Nordic randomised phase 2 comparing 60 Gy in 40 twice-daily fractions with 45 Gy reported a 2-year OS gain of similar shape, 74.2% against 48.1%, and the consistency of two independent trials pointing the same way is a stronger argument than either magnitude taken alone.
Generalisability is where the trial gives up the most. The control arm reached 39.5 months, against 20.8 to 30 months in prior 45 Gy series, meaning the entire cohort outperformed the literature. The investigators attribute this to PET staging, the more conservative VALSG limited-stage definition, exclusion of ECOG 2, and an upper age limit of 70 in a disease whose median age at diagnosis is closer to 67 to 71. Those are credible explanations, and they are also a description of a population most oncologists do not entirely have. Absolute survival should be expected to fall in a less selected group; whether the relative benefit of the boost falls with it is unknown, since the subgroup analyses have not been reported and there was no centralised quality assurance to confirm that the dose actually delivered matched the dose prescribed across 16 centres.
For the local-regional argument, the pattern of failure data is the most persuasive element. Local PFS separated substantially (HR 0.51) while metastasis-free survival did not (HR 0.81, p=0.248), and first-relapse sites were similarly distributed between arms. A chest-confined intervention producing a chest-confined benefit is the result one would predict if the effect is real, and its absence would have been the strongest reason to suspect chance.